Featured Videos

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Neal Shore presented further data from the ALSYMPCA trial. ALSYMPCA is a Phase 3 trial of Ra-223 for the treatment of symptomatic metastatic castrate-resistant prostate cancer (mCRPC) in patients with no known visceral mets. Ra-223, an alpha-emitting pharmaceutical, has been shown to significantly prolong overall survival and time to first symptomatic skeletal event, compared to placebo. Of the 921 patients randomized, 57% and 43% had prior or no prior docetaxel (D+/D-), respectively, and safety data from the predefined ALSYMPCA D subgroups were presented.

auaRegardless of D use, Ra-223 significantly prolonged overall survival (D+, HR = 0.70; D-, HR = 0.69). The risk of skeletal events was also reduced in the D+ and D- groups. D- patients did have lower rates of grade 3 or 4 anemia, neutropenia, and thrombocytopenia compared to the D+ group, but the overall frequency of grade 3 or 4 adverse events was low. A subgroup of 147 patients receiving chemotherapy after Ra-223 demonstrated comparable rates of grade 3 or 4 anemia and neutropenia between D+ and D- groups.

Dr. Shore concluded that Ra-223 significantly prolongs OS with a favorable safety profile in mCRPC patients with symptomatic bone metastases regardless of D use. Rates of grade 3 or 4 hematologic adverse events were slightly higher in D+ patients.

Click HERE to view the poster from this session

Presented by Neal D. Shore, MD, FACS at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Myrtle Beach, SC USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com



Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 1

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.